TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a U.S. clinical-stage biopharmaceutical company founded in 2001 that discovers and develops small-molecule drugs targeting debilitating diseases, operating with 11–50 employees and trading on OTC pink sheets as TLOG.
- Company typePublic
- Founded2001
- HeadquartersMalvern, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What TetraLogic Pharmaceuticals does
TetraLogic Pharmaceuticals is a U.S.-based, clinical-stage biopharmaceutical company founded in 2001 and headquartered in Malvern, Pennsylvania. Per the firm's stated positioning, it discovers and develops small-molecule drugs intended to treat debilitating diseases and conditions. In the available source material, no specific drug candidates, approved products, or therapeutic offerings have been identified — the company is described at the platform/category level only. Its operating footprint is small (11–50 employees), and the public profile surfaces a dedicated Regulatory Affairs and Quality Control capability under named leadership, with John M. Gill as CEO and Sherri Carenzo as Head of Regulatory Affairs and Quality Control Manager.
The capital history shows a venture-backed clinical developer that completed multiple Series 2 and Series 3 financings between 2006 and 2011 — led primarily by Clarus Ventures with Latterell Venture Partners co-leading the Series 2 and a broad investor syndicate including Amgen Ventures, Pfizer Venture Investments, HealthCare Ventures, Hatteras Venture Partners, Quaker BioVentures, Novitas Capital, The Vertical Group, and Nextech Invest — for total disclosed private funding of roughly $164M. The company subsequently expanded its pipeline in April 2014 by acquiring Shape Pharmaceuticals for $13M and raised an additional $47M in June 2014. It is publicly traded on OTC Markets under ticker TLOG (otcpink:TLOG).
The financial profile disclosed through 2015 shows no revenue line item, with operating losses reported annually in the $17–38M range and net losses reaching roughly $50M in 2015 — consistent with a pre-commercial drug developer fully funded by equity capital rather than product cash flow. The combination of persistent cash burn, small headcount, no disclosed revenue, and migration to the OTC pink sheets (rather than a major exchange) is consistent with a company that is operating but financially constrained, with no visible mechanism for near-term commercialization absent a partnership, licensing deal, or capital event not present in the source data.
TetraLogic Pharmaceuticals firmographics
Firmographics- Name
- TetraLogic Pharmaceuticals
- Website
- https://tetralogicpharma.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TetraLogic Pharmaceuticals is a U.S. clinical-stage biopharmaceutical company founded in 2001 that discovers and develops small-molecule drugs targeting debilitating diseases, operating with 11–50 employees and trading on OTC pink sheets as TLOG.
- Ownership category
- akta.pro rank
TetraLogic Pharmaceuticals industry classification
Industry- Product category
- Biopharmaceuticals — Small Molecule Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where TetraLogic Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Markets served
TetraLogic Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
TetraLogic Pharmaceuticals product offering
Product offeringCore offering
TetraLogic Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs intended for the treatment of debilitating diseases and conditions. The company operates as a development-stage firm with no reported product revenue between 2011 and 2015, generating value through internal R&D and acquisitions such as Shape Pharmaceuticals.
Product overview
TetraLogic Pharmaceuticals is a biopharmaceutical company. Based on the available source data, no specific pharmaceutical products, drug candidates, or therapeutic offerings have been identified. The company is publicly traded on the OTCMKTS exchange under ticker symbol TLOG and has been the subject of comparative financial analyses with other biopharmaceutical firms such as Arcutis Biotherapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- Small Molecule Therapeutics Pipeline Pipeline of small molecule drug candidates intended for the treatment of debilitating diseases and conditions; no specific branded products or approved drugs are named in the source data, and the company reported no revenue from 2011–2015, consistent with a development-stage offering.
- Shape Pharmaceuticals Asset Portfolio Drug development assets acquired through the 2014 acquisition of Shape Pharmaceuticals, integrated into TetraLogic's small-molecule research and development pipeline for debilitating diseases.
Companies that use TetraLogic Pharmaceuticals
Customer profileIdeal customer profiles1 record
TetraLogic Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
TetraLogic Pharmaceuticals partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights3 records
TetraLogic Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Verastem: Clinical-stage biopharmaceutical company developing small-molecule drugs targeting cancer stem cells. Closely comparable in scale, small-molecule modality, oncology focus, and small-cap public-company structure.
- MEI Pharma: Late-stage clinical biopharmaceutical company developing small-molecule oncology drugs. Comparable in business model, small-molecule focus, capital intensity, and small public-company scale.
- Arcutis Biotherapeutics: Small-cap clinical-stage biopharmaceutical company developing innovative therapeutics for serious skin diseases. Directly cited in TetraLogic's own comparative financial analysis as a benchmark peer, with comparable scale and small-molecule/specialty-pharma profile.
- Aprea Therapeutics: Clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting cancer. Highly comparable in small-molecule modality, oncology focus, and clinical-stage small-cap public-company profile.
- Trillium Therapeutics: Clinical-stage immuno-oncology company developing small-molecule and biologic therapeutics for serious diseases. Comparable in size, clinical-stage structure, and oncology/specialty pharma focus.
- Karyopharm Therapeutics: Clinical-stage pharmaceutical company developing small-molecule therapies for cancer and other serious diseases. Comparable in modality, therapeutic area, and small-cap clinical-stage profile.
- Deciphera Pharmaceuticals: Developer of small-molecule kinase inhibitors for oncology with similar small-cap public-company profile, clinical-stage structure, and targeted-therapy approach to debilitating diseases.
- Curis: Clinical-stage small-molecule oncology drug developer with a similar small-cap, loss-making, public-company profile and focus on targeted therapeutics for serious diseases.
Emerging players
- Forma Therapeutics: Clinical-stage biopharmaceutical company developing small-molecule therapies for rare hematologic diseases and cancers. Comparable in small-molecule platform approach and clinical-stage scale.
- Constellation Pharmaceuticals: Clinical-stage biopharmaceutical company developing small-molecule epigenetic therapies for cancer and other serious diseases. Comparable in modality, therapeutic-area focus, and small-cap clinical-stage scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
TetraLogic Pharmaceuticals social profiles
Digital presenceTetraLogic Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
TetraLogic Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
TetraLogic Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds9 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TetraLogic Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TetraLogic Pharmaceuticals
What does TetraLogic Pharmaceuticals do?
TetraLogic Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs intended for the treatment of debilitating diseases and conditions. The company operates as a development-stage firm with no reported product revenue between 2011 and 2015, generating value through internal R&D and acquisitions such as Shape Pharmaceuticals.
Is TetraLogic Pharmaceuticals a public or private company?
TetraLogic Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was TetraLogic Pharmaceuticals founded?
TetraLogic Pharmaceuticals was founded in 2001. It employs 11 to 50 people.
Where is TetraLogic Pharmaceuticals based?
TetraLogic Pharmaceuticals is headquartered in Malvern, United States, in the North America region.
Who are TetraLogic Pharmaceuticals's main competitors?
Direct peers on record are Verastem, MEI Pharma, Arcutis Biotherapeutics, Aprea Therapeutics, Trillium Therapeutics, Karyopharm Therapeutics, Deciphera Pharmaceuticals and Curis. Emerging players are Forma Therapeutics and Constellation Pharmaceuticals.
Does TetraLogic Pharmaceuticals have an API?
No public API is recorded for TetraLogic Pharmaceuticals.
What industry is TetraLogic Pharmaceuticals in?
TetraLogic Pharmaceuticals's product category is Biopharmaceuticals — Small Molecule Therapeutics. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.